Medications for Diffuse Large Bcell Lymphoma Recurrent

3 results

  • monjuvi

    (Tafasitamab-cxix)
    MorphoSys US Inc.
    MONJUVI, in combination with lenalidomide, is indicated for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplant. Approval is based on overall response rate and may require further verification of clinical benefit.

  • yescarta

    (axicabtagene ciloleucel)
    Kite Pharma, Inc.
    YESCARTA is indicated for adult patients with refractory or relapsed large B-cell lymphoma after first-line treatment or following two or more therapies. It also treats relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, although approval for follicular lymphoma is contingent on further studies.

  • zynlonta

    (loncastuximab tesirine)
    ADC Therapeutics America, Inc.
    ZYNLONTA is indicated for adult patients with relapsed or refractory large B-cell lymphoma following two or more systemic therapies, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and variants. Approval is based on overall response rates, with continued approval dependent on further confirmation of clinical benefit.